| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 18.344 | 29.230 | 21.459 | 15.587 | 473 | 0 | 0 | - | 0 | 0 |
| Total Income - EUR | 18.344 | 29.230 | 21.459 | 15.587 | 473 | 0 | 0 | - | 0 | 0 |
| Total Expenses - EUR | 16.855 | 38.276 | 29.331 | 20.010 | 584 | 0 | 0 | - | 3.446 | 7.434 |
| Gross Profit/Loss - EUR | 1.488 | -9.045 | -7.872 | -4.423 | -111 | 0 | 0 | - | -3.446 | -7.434 |
| Net Profit/Loss - EUR | 938 | -9.648 | -8.087 | -4.579 | -131 | 0 | 0 | - | -3.446 | -7.434 |
| Employees | 1 | 2 | 3 | 2 | 1 | 0 | 0 | - | 0 | 0 |
Check the financial reports for the company - Oprisan M.d. Company Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 427 | 420 | 412 | 404 | 396 | 388 | - | 194 | 193 |
| Current Assets | 23.478 | 8.433 | 8.120 | 12.759 | 12.308 | 12.360 | 11.668 | - | 8.374 | 894 |
| Inventories | 20.307 | 7.172 | 6.095 | 11.907 | 11.261 | 11.048 | 10.803 | - | 7.551 | 75 |
| Receivables | 3.131 | 1.237 | 1.935 | 691 | 757 | 1.028 | 587 | - | 541 | 538 |
| Cash | 40 | 24 | 91 | 161 | 290 | 284 | 278 | - | 283 | 281 |
| Shareholders Funds | 2.855 | -6.822 | -14.793 | -19.100 | -18.862 | -18.504 | -18.087 | - | -21.534 | -28.848 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | 40 | 40 |
| Debts | 20.623 | 15.682 | 23.333 | 32.271 | 31.574 | 31.260 | 30.143 | - | 30.102 | 29.934 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4719 - 4719" | |||||||||
| CAEN Financial Year |
4719
|
|||||||||
Comments - Oprisan M.d. Company Srl